[Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy].
Fifty patients with benign prostatic hypertrophy were treated with chlormadinone acetate (CMA) at the dose of 50 mg/day for 12 months. Subjective symptoms and objective findings were evaluated before, and after 4 and 12 months of treatment. Better improvement was observed in all of the subjective symptoms and in almost all the parameters of objective findings, in proportion to the period of CMA treatment. Generally speaking, 12 months of treatment was more effective than 4 months of treatment. Two patients had impotence (4.0%). Both of them complained of side effects within 4 months after treatment, but they were not severe. In conclusion, long-term treatment of benign prostatic hypertrophy with CMA was useful.
Kogawa
T
T
Department of Urology, Hirosaki University Hospital.
Yanagiya
H
H
Takashima
T
T
Higashino
I
I
Kudo
T
T
Suzuki
T
T
Mikuni
T
T
Kido
K
K
Tsukui
A
A
Yagihashi
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D002715:Chlormadinone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors; D014521:Urethra / Q000473:pathology; D014563:Urodynamics
D002715:Chlormadinone Acetate